IL1B and breast carcinoma: By using a mouse breast cancer model with IL-1β deficiency or upon treatment with anti–IL-1β Abs, Kaplanov et al. showed that blocking IL-1β induces tumor regression, improves antitumor cell immunity and synergizes with anti-PD-1 incrementing its action (Kaplanov et al., 2019).